This proposal focuses on penile acquisition of pathogenic SIVsmm infection since this transmission route accounts for nearly half of the global HIV-1 pandemic and has been understudied in comparison with other mucosal routes of transmission. Elucidation of the bottleneck to SIV/HIV transmission and the molecular and cellular mechanisms underlying successful infection at epithelial and mucosal surfaces of the penis could be instrumental in the design of effective vaccines. Our laboratories have taken significant steps toward addressing these goals by developing and validating an experimental strategy with which to identify, enumerate, and molecularly clone transmitted/founder HIV-1 and SIV genomes that are responsible for productive infection (Keele 2008;Keele 2009;Salazar 2009;Stone 2010;Bar 2010;Li 2010a,b). In this project, we will test the following hypothesis: Genetically-diverse, rhesus macaque-adapted, pathogenic SIVsmm viruses will productively infect Indian rhesus macaques by atraumatic penile inoculation and lead to persistent replication and pathogenicity. Analysis of transmitted/founder viruses in this transmission model will reveal the extent of the mucosal bottleneck and the impact of neutralizing and binding antibodies on blocking infection. A test of this hypothesis will provide mechanistic insights into the biology of penile SIV/HIV acquisition, the high transmissibility of SIV/HIV during the acute infection period, and the relative protective effect of anti-SIV/HIV antibodies in chronic infection on forward transmission.
Specific aims are: (i) To productively infect Indian rhesus macaques by atraumatic penile inoculation of genetically-divergent, macaque-adapted, pathogenic SIVsmm viruses from acute infection plasma;(ii) To identify by single genome amplification and to molecularly clone transmitted/founder viruses from these animals;(iii) To determine if plasma from acutely infected animals contains virus that is more infectious and transmissible on a per virion basis than plasma from the same animals in chronic phase infection;(iv) To characterize quantitatively the bottleneck to penile transmission compared with intravenous inoculation;and (v) To determine if chronic phase plasma contains SIV-specific antibodies that prevent penile or intravenous virus acquisition. A key deliverable of this project, in addition to new scientific insights into penile transmission and mechanisms underlying 'acute- to-acute'infection, will be 8 new molecular clones of transmitted/founder viruses resulting from penile acquisition that represent widely divergent SIVsmm genetic lineages for use as potential vaccine challenge stocks and in further studies of SIV transmission biology.

Public Health Relevance

It is widely believed that a sterilizing HIV or SIV vaccine will need to interrupt the earliest sequence of infection events. This project will develop a new rhesus macaque penile transmission model using genetically-divergent, pathogenic SIVsmm viruses and it will characterize the mucosal bottleneck and determine the vulnerability of early infection events to antibody-mediated protection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI094604-05
Application #
8607114
Study Section
Special Emphasis Panel (ZAI1-RRS-A (J1))
Program Officer
Warren, Jon T
Project Start
2011-03-01
Project End
2016-02-29
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
5
Fiscal Year
2014
Total Cost
$662,364
Indirect Cost
$245,520
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Astronomo, Rena D; Santra, Sampa; Ballweber-Fleming, Lamar et al. (2016) Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine 14:97-111
Mason, Rosemarie D; Welles, Hugh C; Adams, Cameron et al. (2016) Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. PLoS Pathog 12:e1005537
Lopker, Michael J; Del Prete, Gregory Q; Estes, Jacob D et al. (2016) Derivation and Characterization of Pathogenic Transmitted/Founder Molecular Clones from Simian Immunodeficiency Virus SIVsmE660 and SIVmac251 following Mucosal Infection. J Virol 90:8435-53
Li, Hui; Wang, Shuyi; Kong, Rui et al. (2016) Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc Natl Acad Sci U S A 113:E3413-22
Santra, Sampa; Tomaras, Georgia D; Warrier, Ranjit et al. (2015) Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathog 11:e1005042
Asmal, Mohammed; Luedemann, Corinne; Lavine, Christy L et al. (2015) Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. Virology 475:37-45
Del Prete, Gregory Q; Ailers, Braiden; Moldt, Brian et al. (2014) Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. Cell Host Microbe 16:412-8
Del Prete, Gregory Q; Park, Haesun; Fennessey, Christine M et al. (2014) Molecularly tagged simian immunodeficiency virus SIVmac239 synthetic swarm for tracking independent infection events. J Virol 88:8077-90
Del Prete, Gregory Q; Scarlotta, Matthew; Newman, Laura et al. (2013) Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J Virol 87:4584-95
Lopker, Michael; Easlick, Juliet; Sterrett, Sarah et al. (2013) Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock. J Virol 87:5477-92

Showing the most recent 10 out of 25 publications